Donepezil Hydrochloride
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease
Conditions
Alzheimer's Disease
Trial Timeline
Jun 1, 2013 → Jul 22, 2016
NCT ID
NCT02162264About Donepezil Hydrochloride
Donepezil Hydrochloride is a pre-clinical stage product being developed by Eisai for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02162264. Target conditions include Alzheimer's Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02448784 | Pre-clinical | Completed |
| NCT02162264 | Pre-clinical | Completed |
| NCT02162251 | Pre-clinical | Completed |
| NCT01251718 | Pre-clinical | Completed |
| NCT01129596 | Pre-clinical | Completed |
| NCT00477659 | Approved | Completed |
| NCT00165750 | Approved | Terminated |
| NCT00165724 | Approved | Completed |
| NCT00165737 | Phase 3 | Completed |
| NCT00165659 | Phase 2 | Completed |
| NCT00096473 | Phase 3 | Completed |
Competing Products
20 competing products in Alzheimer's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY450139 + Placebo | Eli Lilly | Phase 3 | 77 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 52 |
| GSK4527226 | Alector | Phase 2 | 44 |
| GSK4527226 | Alector | Phase 2 | 44 |
| AL002 | Alector | Phase 2 | 44 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| simufilam | Cassava Sciences | Phase 2 | 44 |
| Remternetug + Placebo | Eli Lilly | Phase 3 | 77 |
| solanezumab | Eli Lilly | Phase 2 | 52 |
| LY2886721 + Placebo | Eli Lilly | Phase 1 | 33 |
| Gantenerumab + Gantenerumab + Gantenerumab + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. | Yuhan | Approved | 85 |
| FK962 | Astellas Pharma | Phase 2 | 52 |
| ASP0777 + Placebo | Astellas Pharma | Phase 1 | 33 |
| Elenbecestat + Placebo | Eisai | Phase 3 | 77 |
| Donepezil | Eisai | Approved | 85 |
| Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg) | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride | Eisai | Phase 3 | 77 |
| Lecanemab IV + Placebo + Lecanemab SC | Eisai | Phase 3 | 77 |